When does mepolizumab lose exclusivity (and why the date can vary)?
Loss of exclusivity for mepolizumab can mean different things depending on the market and the legal mechanism involved (patent expiry vs. regulatory exclusivity). The date therefore varies by country and by which exclusivity regime applies.
The only widely used sources for “loss of exclusivity” timing are:
- Patent expiry dates for mepolizumab’s key patents in each jurisdiction.
- Any additional regulatory exclusivities in that jurisdiction (for example, marketing authorization data/market exclusivity periods, if applicable).
Because the timing differs by country and because “loss of exclusivity” is not a single global event, you generally need to check the specific jurisdiction’s patent register and regulatory exclusivity rules.
What countries are typically meant in this question?
People usually ask this for one of the largest markets (US, EU, UK) since those determine when biosimilars can launch.
To give a specific date, you must specify the country (or region) you care about, such as:
- United States
- European Union (and whether you mean EMA/EU-wide or a specific member state)
- United Kingdom
How “loss of exclusivity” relates to biosimilar launch timing
Even after exclusivity ends, a biosimilar’s launch depends on additional factors, such as:
- Whether patent litigation is still in play or a “patent clock” settlement delays launch.
- Regulatory approval/authorization timing for the biosimilar product.
- Product-specific labeling and substitution rules in the local market.
So “loss of exclusivity” is the permission boundary in principle, but real-world launch can still shift.
If you tell me your market, I can pin down the date
Reply with the country/region you mean (e.g., US or EU/UK) and, if you have it, the form (typically Nucala). Then I can provide the specific exclusivity-loss date(s) relevant to that jurisdiction.
Sources
No sources were provided in the prompt.